Professional
Added to YB: 2024-04-16
Pitch date: 2024-04-10
AXSM [bullish]
Axsome Therapeutics, Inc.
+108.37%
current return
Author Info
No bio for this author
Company Info
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Market Cap
$7.0B
Pitch Price
$71.11
Price Target
N/A
Dividend
N/A
EV/EBITDA
-37.72
P/E
-29.96
EV/Sales
12.36
Sector
Pharmaceuticals
Category
growth
ClearBridge Small Cap Strategy New Portfolio Holding: Axsome Therapeutics, Inc.
AXSM: CNS biopharma w/ 2 marketed drugs, 5 late-stage trials, 10 target indications, 100M+ patient TAM. If successful data in '24, could have 6 indications by '25. $200M net cash, expected profitable in '24. Downside protection + considerable upside optionality on trial success.
Read full article (1 min)